Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Morgan Simpson

Nurse Practitioner, Primary Care Brownsville, TN Nurse Practitioner

NPI 1548707409 CMS profile 10984640

Clarey R Dowling Mdpc, 2569 N Washington Ave, Brownsville, TN 38012

Open in the dashboard

General payments

$1,747

96 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morgan Simpson of Brownsville, TN is reported in the CMS Open Payments database as having received $1,747 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $888 52
2024 General $580 28
2023 General $162 9
2022 General $105 6
2021 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morgan Simpson
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Morgan Simpson were reported at $888. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Morgan Simpson Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $12 $137 $39–$445 $132
2022 $105 $139 $44–$421 $149
2023 $162 $163 $53–$481 $160
2024 $580 $176 $54–$511 $164
2025 $888 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $342 17 payments
  2. AbbVie, Inc. $339 23 payments
  3. Novo Nordisk Inc $278 14 payments
  4. ITI, Inc. $169 10 payments
  5. Lilly USA, LLC $139 8 payments
  6. Astellas Pharma US Inc $89 3 payments
  7. Phathom Pharmaceuticals, Inc. $82 4 payments
  8. Pfizer Inc. $61 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $58 3 payments
  10. Seqirus USA Inc $29 1 payment
  11. Other $159 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,747 96 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $171 9 payments
  2. Ozempic $171 8 payments
  3. VRAYLAR Neuroscience $164 8 payments
  4. VRAYLAR Neuroscience $164 14 payments
  5. CAPLYTA $155 9 payments
  6. MOUNJARO $139 8 payments
  7. AIRSUPRA $114 5 payments
  8. Wegovy $107 6 payments
  9. Veozah $89 3 payments
  10. BREZTRI $78 4 payments
  11. Other $583 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

10,347

Median for Nurse Practitioner: 389

Drug cost

$920,809

Median for Nurse Practitioner: $21,885

Branded share of claims

25.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 137 $164,005
Ozempic Semaglutide Brand 128 $127,996
Eliquis Apixaban Brand 167 $120,326
Januvia Sitagliptin Phosphate Brand 177 $112,931
Farxiga Dapagliflozin Propanediol Brand 152 $100,783
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 78 $56,238
Jardiance Empagliflozin Brand 27 $26,946
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 34 $22,141
Wegovy Semaglutide Brand 13 $17,941
Trulicity Dulaglutide Brand 14 $15,088

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$177,192

Of which drugs: $16,058

Medicare patients

493

Average age 75

Services billed

22,362

291 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 33%
Ischemic heart disease 28%
Depression 20%
Chronic kidney disease 18%
Atrial fibrillation 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 133 133 $10,882
Vaccine for influenza for injection into muscle 90662 Office 34 34 $2,782
Injection, methylprednisolone acetate, 1 mg J1010 Office 143 16,560 $1,528
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 12 12 $257
Injection, ceftriaxone sodium, per 250 mg J0696 Office 75 471 $153
Injection, methylprednisolone acetate, 80 mg J1040 Office 30 30 $148
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 156 936 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $106
$106 — —
Veozah
  • Astellas Pharma US Inc $89
$89 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $63
$63 — —
Wegovy
  • Novo Nordisk Inc $44
$44 13 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record